ARS Pharmaceuticals Inc

SPRY

10.030USD

+0.360+3.72%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

ARS Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

41 / 392

Overall Ranking

147 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

ARS Pharmaceuticals Inc Highlights

StrengthsRisks

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 6674.24% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 89.15M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is -12.46, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 88.46M shares, decreasing 9.88% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.50M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.06.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

28.167

Target Price

+191.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of ARS Pharmaceuticals Inc is 8.28, ranking 49 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 32.50M, representing a year-over-year increase of 1471.62%, while its net profit experienced a year-over-year increase of 167.41%.

Score

Industry at a Glance

Previous score

8.28

Change

0



Financials

5.58

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of ARS Pharmaceuticals Inc is 6.91, ranking 203 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -12.46, which is -1547.21% below the recent high of 180.34 and -830.68% above the recent low of -115.98.

Score

Industry at a Glance

Previous score

6.91

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 41/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of ARS Pharmaceuticals Inc is 9.33, ranking 5 out of 392 in the Biotechnology & Medical Research industry. The average price target is 31.00, with a high of 35.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

9.33

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of ARS Pharmaceuticals Inc is 6.74, ranking 181 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 12.25 and the support level at 8.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.55

Change

0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of ARS Pharmaceuticals Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 89.49%, representing a quarter-over-quarter increase of 0.81%. The largest institutional shareholder is The Vanguard, holding a total of 3.50M shares, representing 3.54% of shares outstanding, with 0.13% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

10.86M

--

OrbiMed Advisors, LLC

8.29M

--

Deerfield Management Company, L.P.

7.50M

-1.40%

Lowenthal (Richard E)

6.83M

-14.34%

Pratik Shah Living Trust

4.82M

--

Tanimoto (Sarina)

4.57M

-10.85%

Rubric Capital Management LP

4.50M

+247.52%

BlackRock Institutional Trust Company, N.A.

4.35M

+10.68%

SR One Capital Management, LP

4.01M

--

abrdn Inc.

3.10M

+106.11%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ARS Pharmaceuticals Inc is 4.29, ranking 93 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.77. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

ARS Pharmaceuticals Inc

SPRY

7.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment